Advertisement

Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases

      Highlights

      • Only 2.7% of ongoing clinical trials are incorporating technology-based outcomes.
      • Sensor-based technology accounted for over 75% of these technologies applied.
      • Gait and physical activity were the most common targeted domains.
      • Validating relevant endpoints and standardizing measures should increase adoption.

      Abstract

      Introduction

      We sought to review the landscape of past, present, and future use of technology-based outcome measures (TOMs) in clinical trials of neurodegenerative disorders.

      Methods

      We systematically reviewed PubMed and ClinicalTrials.gov for published and ongoing clinical trials in neurodegenerative disorders employing TOMs. In addition, medical directors of selected pharmaceutical companies were surveyed on their companies' ongoing efforts and future plans to integrate TOMs in clinical trials as primary, secondary, or exploratory endpoints.

      Results

      We identified 164 published clinical trials indexed in PubMed that used TOMs as outcome measures in Parkinson disease (n = 132) or other neurodegenerative disorders (n = 32). The ClinicalTrials.gov search yielded 42 clinical trials using TOMs, representing 2.7% of ongoing trials. Sensor-based technology accounted for over 75% of TOMs applied. Gait and physical activity were the most common targeted domains. Within the next 5 years, 83% of surveyed pharmaceutical companies engaged in neurodegenerative disorders plan to deploy TOMs in clinical trials.

      Conclusion

      Although promising, TOMs are underutilized in clinical trials of neurodegenerative disorders. Validating relevant endpoints, standardizing measures and procedures, establishing a single platform for integration of data and algorithms from different devices, and facilitating regulatory approvals should advance TOMs integration into clinical trials.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Parkinsonism & Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chan P.H.
        • Wong C.K.
        • Pun L.
        • Wong Y.F.
        • Wong M.M.
        • Chu D.W.
        • Siu C.W.
        Diagnostic performance of an automatic blood pressure measurement device, Microlife WatchBP Home A, for atrial fibrillation screening in a real-world primary care setting.
        BMJ Open. 2017; 7: e013685
        • Espay A.J.
        • Bonato P.
        • Nahab F.B.
        • Maetzler W.
        • Dean J.M.
        • Klucken J.
        • Eskofier B.M.
        • Merola A.
        • Horak F.
        • Lang A.E.
        • Reilmann R.
        • Giuffrida J.
        • Nieuwboer A.
        • Horne M.
        • Little M.A.
        • Litvan I.
        • Simuni T.
        • Dorsey E.R.
        • Burack M.A.
        • Kubota K.
        • Kamondi A.
        • Godinho C.
        • Daneault J.F.
        • Mitsi G.
        • Krinke L.
        • Hausdorff J.M.
        • Bloem B.R.
        • Papapetropoulos S.
        Movement disorders society task force on technology, technology in Parkinson's disease: challenges and opportunities.
        Mov. Disord. 2016; 31: 1272-1282
        • Ozinga S.J.
        • Machado A.G.
        • Miller Koop M.
        • Rosenfeldt A.B.
        • Alberts J.L.
        Objective assessment of postural stability in Parkinson's disease using mobile technology.
        Mov. Disord. 2015; 30: 1214-1221
        • Horak F.B.
        • Mancini M.
        Objective biomarkers of balance and gait for Parkinson's disease using body-worn sensors.
        Mov. Disord. 2013; 28: 1544-1551
        • Mariani B.
        • Jimenez M.C.
        • Vingerhoets F.J.
        • Aminian K.
        On-shoe wearable sensors for gait and turning assessment of patients with Parkinson's disease.
        IEEE Trans. Biomed. Eng. 2013; 60: 155-158
        • Cavanaugh J.T.
        • Ellis T.D.
        • Earhart G.M.
        • Ford M.P.
        • Foreman K.B.
        • Dibble L.E.
        Capturing ambulatory activity decline in Parkinson's disease.
        J. Neurol. Phys. Ther. 2012; 36: 51-57
        • Rahimi F.
        • Bee C.
        • Duval C.
        • Boissy P.
        • Edwards R.
        • Jog M.
        EMAP group, Using ecological whole body kinematics to evaluate effects of medication adjustment in Parkinson disease.
        J. Park. Dis. 2014; 4: 617-627
        • Dickersin K.
        • Scherer R.
        • Lefebvre C.
        Identifying relevant studies for systematic reviews.
        BMJ. 1994; 309: 1286-1291
        • Lieber B.
        • Taylor B.E.
        • Appelboom G.
        • McKhann G.
        • Connolly E.S.
        Motion sensors to assess and monitor medical and surgical management of Parkinson disease.
        World Neurosurg. 2015; 84: 561-566
        • Bhidayasiri R.
        • Sringean J.
        • Thanawattano C.
        Sensor-based evaluation and treatment of nocturnal hypokinesia in Parkinson's disease: an evidence-based review.
        Park. Relat. Disord. 2016; 22: S127-S133
        • van Lummel R.C.
        • Walgaard S.
        • Pijnappels M.
        • Elders P.J.
        • Garcia-Aymerich J.
        • van Dieën J.H.
        • Beek P.J.
        Physical performance and physical activity in older adults: associated but separate domains of physical function in old age.
        PLoS One. 2015; 10: e0144048
        • Ellis T.
        • Cavanaugh J.T.
        • Earhart G.M.
        • Ford M.P.
        • Foreman K.B.
        • Dibble L.E.
        Which measures of physical function and motor impairment best predict quality of life in Parkinson's disease?.
        Park. Relat. Disord. 2011; 17: 693-697
        • Berganzo K.
        • Tijero B.
        • Gonzalez-Eizaguirre A.
        • Somme J.
        • Lezcano E.
        • Gabilondo I.
        • Fernandez M.
        • Zarranz J.J.
        • Gomez-Esteban J.C.
        Motor and non-motor symptoms of Parkinson's disease and their impact on quality of life and on different clinical subgroups.
        Neurologia. 2014; 31: 585-591
        • Valappil R.A.
        • Black J.E.
        • Broderick M.J.
        • Carrillo O.
        • Frenette E.
        • Sullivan S.S.
        • Goldman S.M.
        • Tanner C.M.
        • Langston J.W.
        Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease.
        Mov. Disord. 2010; 25: 2296-2303
        • Maetzler W.
        • Liepelt I.
        • Berg D.
        Progression of Parkinson's disease in the clinical phase: potential markers.
        Lancet Neurol. 2009; 8: 1158-1171